PT1858504E - Solução para diálise peritoneal contendo carnitina e apresentando uma biocompatibilidade melhorada - Google Patents
Solução para diálise peritoneal contendo carnitina e apresentando uma biocompatibilidade melhorada Download PDFInfo
- Publication number
- PT1858504E PT1858504E PT06708437T PT06708437T PT1858504E PT 1858504 E PT1858504 E PT 1858504E PT 06708437 T PT06708437 T PT 06708437T PT 06708437 T PT06708437 T PT 06708437T PT 1858504 E PT1858504 E PT 1858504E
- Authority
- PT
- Portugal
- Prior art keywords
- carnitine
- glucose
- mmol
- solution according
- acid
- Prior art date
Links
- 229960004203 carnitine Drugs 0.000 title claims description 52
- 239000000385 dialysis solution Substances 0.000 title claims description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 title 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 78
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 56
- 239000008103 glucose Substances 0.000 claims description 56
- 239000000243 solution Substances 0.000 claims description 56
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 55
- 229960001031 glucose Drugs 0.000 claims description 53
- 238000000502 dialysis Methods 0.000 claims description 36
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 27
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 23
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 23
- 239000000811 xylitol Substances 0.000 claims description 23
- 229960002675 xylitol Drugs 0.000 claims description 23
- 235000010447 xylitol Nutrition 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 20
- -1 polyol pyruvate ester Chemical class 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002357 osmotic agent Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 125000001589 carboacyl group Chemical group 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 229940091250 magnesium supplement Drugs 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 150000004728 pyruvic acid derivatives Chemical class 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- DYEQJABLISMNPH-UHFFFAOYSA-N 1,1-dihydroxypropan-2-one;2-oxopropanoic acid Chemical compound CC(=O)C(O)O.CC(=O)C(O)=O DYEQJABLISMNPH-UHFFFAOYSA-N 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 210000005033 mesothelial cell Anatomy 0.000 description 40
- 239000002609 medium Substances 0.000 description 20
- 150000003904 phospholipids Chemical class 0.000 description 15
- 230000012010 growth Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000004303 peritoneum Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000000885 nephron Anatomy 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920002177 Icodextrin Polymers 0.000 description 1
- UHUZBXCDYJGKIY-QDBJXHRASA-N OC[C@H](O)[C@@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O UHUZBXCDYJGKIY-QDBJXHRASA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- NXEQRVMWJYMHIA-BTVCFUMJSA-N carbonic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NXEQRVMWJYMHIA-BTVCFUMJSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 229940016836 icodextrin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2005000130 | 2005-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1858504E true PT1858504E (pt) | 2012-04-10 |
Family
ID=35159907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06708437T PT1858504E (pt) | 2005-03-10 | 2006-02-22 | Solução para diálise peritoneal contendo carnitina e apresentando uma biocompatibilidade melhorada |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080138443A1 (OSRAM) |
| EP (1) | EP1858504B1 (OSRAM) |
| JP (2) | JP4717110B2 (OSRAM) |
| KR (1) | KR101324920B1 (OSRAM) |
| AR (1) | AR054015A1 (OSRAM) |
| AT (1) | ATE539742T1 (OSRAM) |
| CA (1) | CA2599252C (OSRAM) |
| CY (1) | CY1112794T1 (OSRAM) |
| DK (1) | DK1858504T3 (OSRAM) |
| ES (1) | ES2380168T3 (OSRAM) |
| HR (1) | HRP20120177T1 (OSRAM) |
| ME (1) | ME02948B (OSRAM) |
| MX (1) | MX2007010814A (OSRAM) |
| PL (1) | PL1858504T3 (OSRAM) |
| PT (1) | PT1858504E (OSRAM) |
| RS (1) | RS52237B (OSRAM) |
| SI (1) | SI1858504T1 (OSRAM) |
| TW (1) | TWI388318B (OSRAM) |
| WO (1) | WO2006094900A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2365429B1 (es) * | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
| US20190183927A1 (en) * | 2016-08-11 | 2019-06-20 | Sulfilatec, Inc. | Medical and nutritional compositions and methods of use |
| ES2750642A1 (es) * | 2018-09-26 | 2020-03-26 | Univ Vigo | Composición farmacéutica que comprende proteína amiloide P de suero para tratar la insuficiencia renal aguda o crónica |
| EP3912656A1 (en) | 2020-05-19 | 2021-11-24 | CoreQuest Sagl | Peritoneal dialysis solution |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
| JPH08131542A (ja) * | 1994-11-11 | 1996-05-28 | Baxter Kk | 腹膜透析液調製用溶液セット |
| CA2155910C (en) | 1995-08-11 | 1999-12-14 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| GB9714218D0 (en) * | 1997-07-04 | 1997-09-10 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
| WO1999007419A1 (en) | 1997-08-07 | 1999-02-18 | Ajay Gupta | Dialysis solutions containing water soluble vitamins and nutrients |
| DE19748290B8 (de) | 1997-10-31 | 2009-09-03 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
| AU1073400A (en) | 1999-10-11 | 2001-04-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use |
| JP2002282354A (ja) | 2001-03-27 | 2002-10-02 | Jms Co Ltd | 腹膜透析液 |
| GB0108359D0 (en) * | 2001-04-03 | 2001-05-23 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
| ITRM20010337A1 (it) * | 2001-06-14 | 2002-12-16 | Sigma Tau Ind Farmaceuti | Soluzione per la conservazione e perfuzione di organi in attesa che vengano trapiantati. |
| FR2840612B1 (fr) * | 2002-06-06 | 2005-05-06 | Roquette Freres | Polymeres solubles de glucose hautement branches et leur procede d'obtention |
| JP2004016615A (ja) * | 2002-06-19 | 2004-01-22 | Fuso Pharmaceutical Industries Ltd | 晶質浸透圧剤及び膠質浸透圧剤を含有する腹膜透析液 |
| JP4361493B2 (ja) | 2002-12-10 | 2009-11-11 | ガンブロ・ルンディア・エービー | 腹膜透析用薬剤の製造のための医学的溶液を調製する方法 |
| JP2006075195A (ja) * | 2004-09-07 | 2006-03-23 | Jms Co Ltd | Ｌカルニチン含有腹膜透析液 |
-
2006
- 2006-02-20 TW TW095105650A patent/TWI388318B/zh not_active IP Right Cessation
- 2006-02-22 US US11/815,356 patent/US20080138443A1/en not_active Abandoned
- 2006-02-22 PT PT06708437T patent/PT1858504E/pt unknown
- 2006-02-22 CA CA2599252A patent/CA2599252C/en not_active Expired - Lifetime
- 2006-02-22 EP EP06708437A patent/EP1858504B1/en not_active Expired - Lifetime
- 2006-02-22 MX MX2007010814A patent/MX2007010814A/es active IP Right Grant
- 2006-02-22 JP JP2008500161A patent/JP4717110B2/ja not_active Expired - Fee Related
- 2006-02-22 RS RS20120096A patent/RS52237B/sr unknown
- 2006-02-22 WO PCT/EP2006/060162 patent/WO2006094900A1/en not_active Ceased
- 2006-02-22 DK DK06708437.6T patent/DK1858504T3/da active
- 2006-02-22 PL PL06708437T patent/PL1858504T3/pl unknown
- 2006-02-22 ES ES06708437T patent/ES2380168T3/es not_active Expired - Lifetime
- 2006-02-22 AT AT06708437T patent/ATE539742T1/de active
- 2006-02-22 KR KR1020077023099A patent/KR101324920B1/ko not_active Expired - Fee Related
- 2006-02-22 ME MEP-2012-31A patent/ME02948B/me unknown
- 2006-02-22 HR HR20120177T patent/HRP20120177T1/hr unknown
- 2006-02-22 SI SI200631285T patent/SI1858504T1/sl unknown
- 2006-03-09 AR ARP060100884A patent/AR054015A1/es unknown
-
2010
- 2010-06-28 JP JP2010146533A patent/JP5366894B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-30 CY CY20121100325T patent/CY1112794T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1858504B1 (en) | 2012-01-04 |
| JP4717110B2 (ja) | 2011-07-06 |
| MX2007010814A (es) | 2007-11-07 |
| US20080138443A1 (en) | 2008-06-12 |
| ME02948B (me) | 2012-10-31 |
| AR054015A1 (es) | 2007-05-30 |
| CA2599252C (en) | 2013-07-30 |
| JP2008532601A (ja) | 2008-08-21 |
| TWI388318B (zh) | 2013-03-11 |
| TW200714279A (en) | 2007-04-16 |
| RS52237B (sr) | 2012-10-31 |
| SI1858504T1 (sl) | 2012-04-30 |
| DK1858504T3 (da) | 2012-04-30 |
| ES2380168T3 (es) | 2012-05-09 |
| PL1858504T3 (pl) | 2012-05-31 |
| JP2010207630A (ja) | 2010-09-24 |
| EP1858504A1 (en) | 2007-11-28 |
| KR20070116630A (ko) | 2007-12-10 |
| HRP20120177T1 (hr) | 2012-03-31 |
| KR101324920B1 (ko) | 2013-11-01 |
| JP5366894B2 (ja) | 2013-12-11 |
| WO2006094900A1 (en) | 2006-09-14 |
| CY1112794T1 (el) | 2016-02-10 |
| CA2599252A1 (en) | 2006-09-14 |
| ATE539742T1 (de) | 2012-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6214802B1 (en) | Peritoneal dialysis fluid | |
| Ettinger et al. | Cardiac conduction abnormalities produced by chronic alcoholism | |
| Topley et al. | In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. | |
| US20030124503A1 (en) | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof | |
| BRPI0518173B1 (pt) | composiçôes oftálmicas | |
| BRPI1006260B1 (pt) | soluções para hemodiálise e diálise peritoneal compreendendo um ou mais compostos de creatina | |
| PT1617834E (pt) | Utilização de uma composição farmacêutica que contém ácido láctico ou lactato e potássio destinada ao tratamento de edema cerebral ou lesões cerebrais | |
| US20090232908A1 (en) | Stable aqueous solution containing sodium pyruvate, and the preparation and use thereof | |
| US8129430B2 (en) | Method of reducing phosphate nephropathy in a mammal | |
| JPS63502107A (ja) | 貯蔵中赤血球を安定化するための溶液 | |
| JP5366894B2 (ja) | 生体適合性が改善されたカルニチンを含有する腹膜透析液 | |
| Golfman et al. | Cardiac membrane Ca2+-transport in alloxan-induced diabetes in rats | |
| Weinstein et al. | Systemic complications of fluid resuscitation | |
| JP2000038348A (ja) | アルブミン含有腹膜透析液 | |
| Galambos et al. | Hyperalimentation in alcoholic hepatitis. | |
| Steele et al. | Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis | |
| Bech et al. | Effects of long-term coenzyme Q10 and captopril treatment on survival and functional capacity in rats with experimentally induced heart infarction. | |
| Thompson et al. | Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia | |
| US11964087B2 (en) | Peritoneal dialysis solution | |
| Chan | Dietary management of renal failure in infants and children: principles of nutritional therapy and some representative diets | |
| JPH0733601A (ja) | 組織保存用組成物 | |
| BR122026004881A2 (pt) | Solução de diálise peritoneal | |
| WO2011083490A2 (en) | Stable veterinary composition for enhanced phosphorous uptake | |
| Brodkin | Factors Affecting the Binding and Synthesis of Acetylcholine. | |
| Thomas | The Effect of Chlorpromazine on Myocardial Function and Metabolism Following Ischemia and Zero-calcium Injury |